我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

ACEI/ARB与CCB防治高血压病伴慢性肾功能不全患者发生造影剂肾病的效果比较

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第6期
页码:
703-707
栏目:
临床研究
出版日期:
2015-07-15

文章信息/Info

Title:
Comparative study on effect of ACEI/ARBs and CCBs in prevention of contrast-induced nephropathy in patients with hypertension associated with chronic renal insufficiency after coronary artery intervention
作者:
陈彩玲1; 黄 铮1; 赖雯苑1; 滕树恩1; 洪承路1; 赵新军2
(南方医科大学:1.第一附屬医院(南方医院)心内科，2.中医药学院，广东 广州 510515）
Author(s):
CHEN Cai-ling1;  HUANG Zheng1;  LAI Wen-yuan1;  TENG Shu-en1;  HONG Cheng-lu1;  ZHAO Xin-jun2
(1.Department of Cardiology, First Affiliated Hospital, 2.College of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China)
关键词:
高血压病; 慢性肾功能不全; 造影剂肾病; 血管紧张素转换酶抑制剂; 血管紧张素受体阻断剂; 钙离子通道阻断剂
Keywords:
high blood pressure;  chronic renal insufficiency;  contrast-induced nephropathy;  angiotensin-converting enzyme inhibitor;  angiotensin receptor blocker;  calcium channel blockers
分类号:
R692.5
DOI:
-
文献标识码:
A
摘要:
目的 比较血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体阻断剂(ARB)和钙离子通道阻断剂(CCB)对高血压病伴慢性肾功能不全（CKD）患者在介入术后发生造影剂肾病(CIN)的防治效果。方法 回顾分析近6年南方医院内科病房180例高血压病伴CKD 2~3期患者，所有患者均接受了冠脉介入术，并在术前术后使用了水化治疗，术前至少使用了7 d的ACEI/ARB或CCB药物，另设单纯水化对照组；观察3组患者发生CIN的例数，以及术后24、48、72 h及 7d的血清肌酐（SCr）、肌酐清除率（CCr）的变化水平，并记录肾功能恢复的时间。结果 ACEI/ARB组术后发生CIN 20例（占37%)，CCB组术后发生CIN 16例（占20%)，单纯水化组发生28例(占61%)；与单纯水化组比较，两组术后CIN发生率均较低（P<0.05，P<0.01）；CCB组和ACEI/ARB组比较，CCB组的CIN发生率较低（P<0.05）。3组患者介入术后24、48、72 h及7 d的SCr、CCr水平均有明显升高，差异有显著性；与单纯水化组相比，ACEI/ARB组和CCB组的血清SCr、CCr水平在24、48、72 h及7 d的时间点均有所降低，差异有显著性；CCB组与ACEI/ARB组相比，48、72 h及7 d的SCr降低较明显（均P<0.05）。术后14 d，ACEI/ARB组有14例（占70%）CIN患者肾功能恢复至术前水平，CCB组有12例（占75%），单纯水化组有16例（占62%），ACEI/ARB组和CCB比较差异无统计学意义。结论 使用ACEI/ARB 和CCB类药物均可对高血压病并发CKD患者发生CIN有预防作用；CCB类药物优于ACEI/ARB类药物。
Abstract:
AIM To evaluate the efficacy of ACEI/ARBs and CCBs in prevention of contrast-induced nephropathy (CIN) in patients with hypertension associated with chronic renal insufficiency after coronary artery intervention. METHODS We retrospectively analyzed 180 patients with 2-3 phase chronic kidney diseases (CKD) in our hospital. Patients all underwent coronary angioplasty and hydration therapy and were taking ACEI/ARBs drugs or CCBs drugs for at least 7 days prior to surgery. The control group was treated only with hydration. The number of patients who developed CIN in the three groups was compared and the level of serum creatinine (SCr) and creatinine clearance rate (CCr) 24, 48, 72 h and 7 days after coronary angioplasty were recorded. RESULTS CIN occurred in 37% of the patients (20/54) in ACEI/ARBs group, in 20% of the patients (16/80) in CCBs group and 56.5% of the patients (28/46) in hydration control group. Compared with the hydration group, CIN incidence decreased obviously in ACEI/ARBs group and CCBs group after coronary angioplasty (P<0.05, P<0.01). Incidence of CIN in CCBs group was lower than that in ACEI/ARBs group (P<0.05). Compared with preoperative levels, levels of plasma creatinine (SCr) and endogenous creatinine clearance rate (Ccr) significantly increased 24, 48, 72 h and 7 days after surgery in all three groups with significant differences. Compared with hydration control group, levels of plasma SCr and Ccr significantly decreased 24, 48, 72 h and 7 days after surgery in ACEI/ARBs group and CCBs group, with significant differences. Compared with that in ACEI/ARBs group, the SCr level 48, 72 h and 7 days after the surgery in CCBs group was lower (P<0.05). Renal functions recovered to pre-operative levels in 70% of the patients in ACEI/ARBs group at 14 days after operation, in 75% in CCBs group and in 61.5% in hydration group, with no statistical difference between ACEI/ARBs group and CCBs group. CONCLUSION ACEI/ARBs and CCBs drugs are beneficial for the prevention of CIN in patients with chronic renal failure. CCB drugs may be more effective than ACEI/ARB drugs for better prevention of CIN and shorter recovery time in patients with chronic renal failure.

参考文献/References

[1]Listro F,Falsini G,Bolognese L.The chinical burden of contrast media-induced nephropathy[J].Ital heart,2003,4(10):668-676.
[2]Nash K,Hou S.Hospital acquired renal insufficiency[J].Am J Kidney Dis,2002,39(5):930-936.
[3]Rihal CS,Textor SC,Grill DE,et al.Incidence and prognostic importance of acute failure after percutaneous coronary intervention[J].Circulation,2002,105(19):2259-2264.
[4]Majumdar SR,Kjellstrand CM,Tymchak WJ,et al.Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial[J].Am J Kidney Dis,2009,54(4):602-609.
[5]Sudarsky D,Nikolsky E.Contrast-induced nephropathy in interventional cardiology[J].Int J Nephrol Renovasc Dis,2011,4:85-99.
[6]Gupta RK,Kapoor A,Tewari S,et al.Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study[J].Indian Heart J,1999,51(5):521-526.
[7]Dangas G,Iakovou I,Nikolsky E,et al.Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables[J].Am F Cardiol,2005,95(1):13-19.
[8]Oguzhan N,Cilan H,Sipahioglu M,et al.The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with hronic kidney disease[J].Ren Fail,2013,35(4):434-439.
[9]Cirit M,Toprak O,Yesil M,et al.Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy[J].Nephron Clin Pract,2006,104(1):20-27.
[10]Kim SJ,Choi D,Ko YG, et al. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention[J].Am J Cardiol,2011,108(8):1086-1091.
[11]Wong PC,Li Z,Guo J,et al.Pathophysiology of contrast-induced nephropathy[J].Int J Cardiol,2012,158(2):186-192.
[12]Spanberg-Viklund B,Berglund J,Nikonoff T,et al.Does prophylactic treatment with felodipine,a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function?[J].Scand J Urol Nephrol,1996,30(1):63-68.
[13]Rodicio JL,Morales JM,Ruilope LM.Calcium antagonists and the kidney[J].Nephrol Dial Transplant,1990,5(2):81-86.
[14]Arici M, Usalan C, Altun B, et al. Radio conttast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration[J].Int Urol Nephrol,2003,35(2):255-261.

备注/Memo

备注/Memo:
收稿日期：2015-01-05.
通讯作者：黄铮，主任医师，主要从事冠心病防治研究 Email：13802503802@163.com
作者简介：陈彩玲，硕士生 Email：15625084095@163.com
更新日期/Last Update: 2015-07-23